findmyKOL
Clinical trialNCT06567015RecruitingPhase 1/PHASE2Interventional

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

SponsorPierre Fabre MedicamentEnrollment171Non-small Cell Lung Cancer (NSCLC)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Shanghai East Hospital, Tongji University

    Shanghai, China

    Caicun Zhou, Prof.
    Recruiting
  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

    Huang Dingzhi, Prof.
    Recruiting
France
  • Centre Léon Bérard

    Lyon, France

    Aurelie Swalduz, Dr.
    Recruiting
  • Chu Hôpital de la Timone

    Marseille, France

    Pascale Tomasini, Dr.
    Recruiting
  • Institut de Cancérologie de L'Ouest (ico) - René Gauducheau

    Saint-Herblain, France

    Sandrine Hiret, Dr.
    Recruiting
  • Institut Universitaire Du Cancer de Toulouse - Oncopole

    Toulouse, France

    Julien Mazieres, Prof.
    Recruiting
  • Gustave Roussy

    Villejuif, France

    David Planchard, Prof.
    Recruiting
Germany
  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

    Martin Wermke, Prof.
    Recruiting
Netherlands
  • Netherlands Cancer Institute

    Amsterdam, Netherlands

    Gerrina Ruiter, MD PhD.
    Recruiting
Spain
  • Vall D'Hebron Institut D'Oncologia

    Barcelona, Spain

    Enriqueta Felip Font, MD PhD.
    Recruiting
  • Centro Intergral Oncologico Clara Campal (ciocc) (start Madrid)

    Madrid, Spain

    Ramon Yarza, Dr.
    Recruiting
  • Hospital Universitario la Paz

    Madrid, Spain

    Javier de Castro Carpeno, Dr.
    Recruiting
Taiwan
  • National Taiwan University Hospital

    Taipei, Taiwan

    Chi Chi Lin, Dr
    Recruiting
  • Taipei Veterans General Hospital

    Taipei, Taiwan

    Yung-Hung Luo, Dr.
    Recruiting
United States
  • Sarah Cannon Research Institute (scri) (the Scri Oncology Research Consortium)

    Nashville, Tennessee, United States

    Melissa Johnson, Dr.
    Recruiting
  • Oncology Consultants (oc) - Texas Medical Center - Cancer Center

    Houston, Texas, United States

    Julio Peguero, Dr
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3-(3-Chloro-2-methoxyanilino)-7-(2-methoxyethyl)-2-(2-methylpyrimidin-4-yl)-1,5-dihydropyrrolo[3,2-c]pyridin-4-one →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Sept 2024
Primary completion
20 Nov 2027
Completion
31 Jul 2030
Last update posted
22 May 2026
Registered enrollment
171
Registry id
NCT06567015

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-510203-21-00
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.